March 15, 2021 -- Novavax's SARS-CoV-2 vaccine candidate NVX-CoV2373 has a 96.4% efficacy against mild, moderate, and severe disease caused by the original COVID-19 strain, the company's phase III trial found.
The vaccine has an 86.3% efficacy against the B.1.1.7/501Y.V1 variant circulating in the U.K. Additionally, a phase IIB trial demonstrated a 55.4% efficacy against the COVID-19 South African variant, B.1.351, among the HIV-negative trial participants.
In both trials, NVX-CoV2373 demonstrated 100% protection against severe disease, including hospitalization and death.
The firm plans to use the data to serve as the basis for submission to various regulatory agencies worldwide authorizing the vaccine's use, Novavax said.